Showing 1183 results
- https://www.novartis.com/news/media-releases/third-novartis-phase-iii-trial-shows-kisqali-combination-therapy-significantly-improves-pfs-hrher2-advanced-breast-cancerKisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line…
- https://www.novartis.com/news/media-releases/new-novartis-data-presented-asco-find-nearly-half-cml-patients-treated-tasigna-remain-remission-almost-three-years-after-stopping-therapyENESTop and ENESTfreedom data evaluate Treatment-free Remission (TFR) rates at 144 weeks among eligible Ph+ CML-CP patients who stopped Tasigna® Findings further support durability and…
- https://www.novartis.com/news/media-releases/novartis-completes-sale-stake-consumer-healthcare-joint-venture-gsk-usd130-billionBasel, June 1, 2018 - Novartis AG ("Novartis") today announced the completion of the divestment to GlaxoSmithKline PLC ("GSK") of its 36.5 percent stake in a consumer healthcare joint venture (JV)…
- https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-adalimumabSandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology Positive CHMP opinion…
- https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-aimovig-erenumab-prevention-migraineIf approved, Aimovig®(erenumab) is expected to be the first and only available therapy designed specifically for migraine prevention in the EU Positive opinion based on robust data package…
- https://www.novartis.com/news/media-releases/fda-expedites-review-novartis-drug-promacta-first-line-severe-aplastic-anemia-saaPromacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy (…
- https://www.novartis.com/news/media-releases/novartis-international-ag-patient-reported-outcomes-tool-revealed-significant-improvement-symptom-frequency-and-quality-life-domains-entrestoOverall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)[1]…
- https://www.novartis.com/news/media-releases/sandoz-receives-european-commission-approval-zessly-infliximab-gastroenterological-rheumatological-and-dermatological-diseasesEuropean Commission's (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable…
- https://www.novartis.com/news/media-releases/novartis-and-amgen-announce-fda-approval-aimovigtm-erenumab-novel-treatment-developed-specifically-migraine-preventionMigraine is a severe neurologic disease that profoundly impacts millions of patients in the United States Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-…
- https://www.novartis.com/news/media-releases/novartis-data-asco-and-eha-reinforce-companys-commitment-reimagining-cancerResults from the Kisqali® MONALEESA clinical trial program, the largest industry- sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will…
Pagination
- ‹ Previous page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- …
- 119
- › Next page